Truvestments Capital’s Actinium Pharmaceuticals ATNM Stock Holding History

Truvestments Capital’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-60	Closed	-$639	–	688
2022 Q4	$639	Hold	60	–	–	﹤0.01%	857
2022 Q3	$0	Hold	60	–	–	﹤0.01%	622
2022 Q2	$0	Buy	+60	New	+$341	﹤0.01%	644
2022 Q1	–	Sell	-60	Closed	–	–	209
2021 Q4	$0	Hold	60	–	–	﹤0.01%	605
2021 Q3	$1K	Hold	60	–	–	﹤0.01%	569
2021 Q2	$0	Hold	60	–	–	﹤0.01%	625
2021 Q1	$0	Sell	60 -150	-71%	-$1.27K	﹤0.01%	666
2020 Q4	$1K	Buy	+210	New	+$2.28K	﹤0.01%	579
2020 Q3	–	Sell	-211	Closed	-$2K	–	339
2020 Q2	$2K	Buy	+211	New	+$1.6K	﹤0.01%	504
2020 Q1	–	Sell	-359	Closed	-$2K	–	508
2019 Q4	$2K	Hold	359	–	–	﹤0.01%	137
2019 Q3	$2K	Sell	359 -29	-7%	-$202	﹤0.01%	652
2019 Q2	$3K	Hold	388	–	–	﹤0.01%	659
2019 Q1	$6K	Buy	+388	New	+$6.2K	﹤0.01%	572
2018 Q3	$9K	Buy	+402	New	+$8.18K	﹤0.01%	650

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Truvestments Capital's ATNM Position: Q1 2023 in Review

Truvestments Capital sold out of Actinium Pharmaceuticals (ATNM) in Q1 2023, closing a stake of 60 shares — an estimated $639 sold.

Truvestments Capital first reported a position in ATNM in Q3 2018 and held it in 14 quarters. The position peaked at $9K in Q3 2018. 64 funds tracked by Wall St. Rank hold ATNM as of Q1 2023.

Truvestments Capital reported no remaining Actinium Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Truvestments Capital sold 60 Actinium Pharmaceuticals shares in Q1 2023, an estimated $639.
Truvestments Capital first reported a position in Actinium Pharmaceuticals in Q3 2018 and held it in 14 quarters.
Truvestments Capital's Actinium Pharmaceuticals position peaked at $9K in Q3 2018.
64 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2023.

Based on Truvestments Capital's 13F filing for Q1 2023, filed 12 May 2023.